Acorda Therapeutics (ACOR) Now Covered by Analysts at CIBC

Equities research analysts at CIBC began coverage on shares of Acorda Therapeutics (NASDAQ:ACOR) in a research note issued to investors on Thursday, November 9th. The firm set a “market perform” rating on the biopharmaceutical company’s stock.

Several other analysts also recently weighed in on ACOR. Cantor Fitzgerald reissued a “hold” rating and issued a $18.00 price target on shares of Acorda Therapeutics in a research note on Thursday, September 28th. BidaskClub downgraded shares of Acorda Therapeutics from a “hold” rating to a “sell” rating in a research note on Wednesday, August 2nd. ValuEngine raised shares of Acorda Therapeutics from a “sell” rating to a “hold” rating in a research note on Monday, October 2nd. Oppenheimer began coverage on shares of Acorda Therapeutics in a research report on Thursday, November 9th. They issued a “market perform” rating and a $27.00 price objective on the stock. Finally, Jefferies Group boosted their price target on shares of Acorda Therapeutics from $22.00 to $25.00 and gave the company a “hold” rating in a research report on Wednesday, November 1st. Four investment analysts have rated the stock with a sell rating, eleven have assigned a hold rating, two have issued a buy rating and one has issued a strong buy rating to the company. The company currently has a consensus rating of “Hold” and an average target price of $21.47.

Shares of Acorda Therapeutics (NASDAQ ACOR) opened at $20.10 on Thursday. Acorda Therapeutics has a fifty-two week low of $13.60 and a fifty-two week high of $33.00. The company has a current ratio of 2.77, a quick ratio of 2.40 and a debt-to-equity ratio of 0.49.

Acorda Therapeutics (NASDAQ:ACOR) last posted its quarterly earnings results on Tuesday, October 31st. The biopharmaceutical company reported $0.43 earnings per share for the quarter, missing the consensus estimate of $0.69 by ($0.26). The business had revenue of $141.07 million during the quarter, compared to the consensus estimate of $150.64 million. Acorda Therapeutics had a negative return on equity of 8.18% and a negative net margin of 10.25%. The business’s revenue for the quarter was up 4.0% on a year-over-year basis. During the same period in the prior year, the firm earned ($0.04) earnings per share. research analysts expect that Acorda Therapeutics will post -0.07 earnings per share for the current fiscal year.

A number of hedge funds have recently added to or reduced their stakes in ACOR. State Street Corp boosted its stake in Acorda Therapeutics by 52.4% in the 2nd quarter. State Street Corp now owns 2,476,033 shares of the biopharmaceutical company’s stock worth $48,783,000 after purchasing an additional 851,290 shares in the last quarter. Dimensional Fund Advisors LP boosted its stake in Acorda Therapeutics by 29.6% in the 2nd quarter. Dimensional Fund Advisors LP now owns 2,372,868 shares of the biopharmaceutical company’s stock worth $46,745,000 after purchasing an additional 541,418 shares in the last quarter. RA Capital Management LLC boosted its stake in Acorda Therapeutics by 83.8% in the 2nd quarter. RA Capital Management LLC now owns 900,259 shares of the biopharmaceutical company’s stock worth $17,735,000 after purchasing an additional 410,431 shares in the last quarter. Goldman Sachs Group Inc. boosted its stake in Acorda Therapeutics by 306.8% in the 2nd quarter. Goldman Sachs Group Inc. now owns 534,956 shares of the biopharmaceutical company’s stock worth $10,538,000 after purchasing an additional 403,467 shares in the last quarter. Finally, Northern Trust Corp boosted its stake in Acorda Therapeutics by 65.2% in the 2nd quarter. Northern Trust Corp now owns 897,974 shares of the biopharmaceutical company’s stock worth $17,690,000 after purchasing an additional 354,304 shares in the last quarter.

ILLEGAL ACTIVITY WARNING: This piece of content was first published by BBNS and is the sole property of of BBNS. If you are accessing this piece of content on another website, it was illegally copied and reposted in violation of U.S. & international trademark and copyright legislation. The correct version of this piece of content can be accessed at https://baseballnewssource.com/markets/cibc-initiates-coverage-on-acorda-therapeutics-inc-acor/1772308.html.

About Acorda Therapeutics

Acorda Therapeutics, Inc is a biopharmaceutical company. The Company focuses on developing therapies that restore function and improve the lives of people with neurological disorders. As of December 31, 2016, the Company marketed three United States Food and Drug Administration (FDA)-approved therapies, including Ampyra (dalfampridine) Extended Release Tablets, 10 milligram (mg), a treatment to improve walking in patients with multiple sclerosis (MS).

Analyst Recommendations for Acorda Therapeutics (NASDAQ:ACOR)

Receive News & Ratings for Acorda Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Acorda Therapeutics Inc. and related companies with our FREE daily email newsletter.

 


Latest News

Manny Machado Could Change Positions or Uniforms
Manny Machado Could Change Positions or Uniforms
Jack Morris, Alan Trammel Voted by Modern Era Committee into Hall of Fame
Jack Morris, Alan Trammel Voted by Modern Era Committee into Hall of Fame
Yankees and Marlins Continue Stanton Trade Talks
Yankees and Marlins Continue Stanton Trade Talks
Marlins Making Moves, Trade Dee Gordon to Seattle
Marlins Making Moves, Trade Dee Gordon to Seattle
Report: Astros Dallas Keuchel Pitched With Injured Foot
Report: Astros Dallas Keuchel Pitched With Injured Foot
Angels Sign Former Prospect with Braves Kevin Maitan
Angels Sign Former Prospect with Braves Kevin Maitan


Leave a Reply

 
© 2006-2017 BBNS.